aldosterone antagonist


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to aldosterone antagonist: potassium sparing diuretics

aldosterone

 [al-dos´ter-ōn, al´do-ster-ōn″]
the main mineralocorticoid hormone secreted by the adrenal cortex, the principal biological activity of which is the regulation of electrolyte and water balance by promoting the retention of sodium (and, therefore, of water) and the excretion of potassium; the retention of water induces an increase in plasma volume and an increase in blood pressure. Its secretion is stimulated by angiotensin II.
aldosterone antagonist a compound that blocks the action of aldosterone; the group includes potassium sparing diuretics such as spironolactone that compete with aldosterone for receptor sites, thus blocking the aldosterone-dependent exchange of sodium and potassium in the distal tubule.

al·dos·ter·one an·tag·o·nist

an agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, for example, spironolactone, are useful in treating the hypertension of primary hyperaldosteronism or the sodium retention of secondary hyperaldosteronism.

al·dos·ter·one an·tag·o·nist

(al-dos'tĕr-ōn an-tag'ŏ-nist)
An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents (e.g., spironolactone) are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism.

al·dos·ter·one an·tag·o·nist

(al-dos'tĕr-ōn an-tag'ŏ-nist)
Agent that opposes action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention.
References in periodicals archive ?
Among patients with stage 4 or 5 kidney disease, treatment with an aldosterone antagonist was associated with the highest rate of blood pressure control, in 70% of patients.
Total patients receiving aldosterone antagonists in some form###33(47.
The seven interventions are beta-blockers, ACE inhibitors or ARBs, aldosterone antagonists, anticoagulation for atrial fibrillation, cardiac resynchronization therapy, implantable cardioverter-defibrillators, and heart failure education for eligible patients.
Angiotensin converting enzyme inhibitors used in combination with aldosterone antagonists decrease the risk of progressive cardiac failure and sudden cardiac death (24).
6% in controls, suggesting that an elevated baseline natriuretic peptide level may be a biomarker useful in identifying those HFpEF patients most likely to respond to an aldosterone antagonist.
Furthermore, reliable quantification of aldosterone is critical during subsequent suppression testing (in which the definitive confirmation or exclusion of primary aldosteronism depends on the measured aldosterone concentration) and adrenal venous sampling, the results of which largely determine whether a patient is a candidate for unilateral adrenalectomy, or alternatively, treatment with aldosterone antagonist medication (10).
The trial design includes an initial run-in period of up to four weeks, during which patients will be treated with proven, guideline-recommended doses of an ARB, and in some instances with both an ARB and an aldosterone antagonist (AA) as indicated for the subset of diabetic chronic kidney disease patients who also have uncontrolled hypertension.
And aldosterone blockade with an aldosterone antagonist has been shown to improve clinical outcomes in heart failure patients with a depressed left ventricular ejection fraction in RALES, the Randomized Aldactone Evaluation Study (N.
73m2) and heart failure on standard renin-angiotensin-aldosterone-system (RAAS) blocker therapy, RLY5016 dose titration successfully allowed treatment with the maximum labeled dose of the aldosterone antagonist spironolactone while maintaining normal serum potassium levels.
This study wasn't designed to determine why the results contradicted the "impressive benefits of aldosterone antagonist therapy" reported in "pivotal" effica cy trials as well as in a systematic review of randomized clinical trials of the therapy.
Following implementation of the IMPROVE HF physician-based performance interventions, statistically significant improvements in the use of CRT device therapy, aldosterone antagonist drugs and heart failure education were observed across all race groups studied.